Celsius aims to cool down inflammation with new investors and more pharma deals
Broad Institute spinout Celsius Therapeutics is turning up the heat on the financing front as it looks to ice the symptoms of inflammatory bowel disease.
The Cambridge, MA biotech has added $83 million in new financing — a mixture of a Series A extension and Series B funds — to chase its vision of precision therapies across autoimmune diseases and cancer. The Third Rock- and GV-backed startup, founded in 2018, brought in new investors like Amgen Ventures, Amplitude Ventures and Fast Track Initiative.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.